Affiliation:
1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285
Abstract
ABSTRACT
The in vitro activity of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1997. LY333328 MICs at which 90% of the isolates tested were inhibited for
Enterococcus faecalis
(
n
= 351),
Enterococcus faecium
(
n
= 100),
Staphylococcus aureus
(
n
= 593), coagulase-negative
Staphylococcus
species (
n
= 325), and
Streptococcus pneumoniae
(
n
= 110) were 1, 1, 2, 2, and 0.015 μg/ml, respectively. LY333328 demonstrated potent activity against isolates of vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献